Calmark Sweden AB is a privately held Swedish company founded in 2007 based on research performed at Karolinska Institutet in Stockholm. Calmark is based in Karlstad with laboratory and representation office at Greenhose Labs in Stockholm. The company is certified according to the ISO 13485:2003 standard for developers and manufacturers of medical devices.
Torbjörn Andersson, CEO. Torbjörn has over 25 years of experience of general management, product development and sales in the life science industry. Torbjörn holds a BSc in Biochemistry, and a MBA with honors from IMD business school in Lausanne, Switzerland.
Mathias Karlsson, Medical Director, founder. The inventor of the Calmark method. Responsible for the medical development of the method and CEO of Calmark Sweden AB. Mathias is a M.D. and holds a Ph.D. at Karolinska Institutet, Sweden, within the field of perinatal asphyxia and the unique properties of specific cell damage markers that indicate the physiological status of conditions caused by an insufficient oxygen supply in tissue.
Sofia Hiort af Ornäs, CTO, founder. Co-inventor of the Calmark method and responsible for the technical product development at Calmark. Sofia has a background as a M.Sc. in chemical engineering from the Royal Institute of Technology, Sweden. She previously worked for Amersham Biosciences/GE Healthcare and SweTree Technologies, having positions as research engineer, project manager and section manager.
Aida Ilkhechoie, QSA. Aida joined Calmark in August 2010 and she is working within Quality Assurance and Regulatory Affairs. Aida has a B.Sc. in Medical engineering from the Royal Institute of Technology and has previously worked within QA in the medical device industry.
Board of Directors
Hjalmar Didrikson, Chairman of the board since 2010. Hjalmar is co-founder of investment firm Alfvén & Didrikson. In 2010, Hjalmar left Northern Europe’s leading private equity group, EQT. He was with EQT from 2006 and managed inter alia EQT’s IPO/sale of Duni AB and public offers for Q-Med AB and HTL-Strefa SA and also served on the Boards of a handful of EQT portfolio companies. In 2004-6 he worked with one of Norway’s leading private equity funds, FSN Capital in Oslo, as an Investment Manager. In 1998-2004 he was with UBS Investment Bank in London as a Corporate Finance adviser to large European companies and investment institutions. He holds a M.Sc. from the Stockholm School of Economics with exchange studies at the MBA program of New York University, Leonard N. Stern School of Business.
Mathias Karlsson, board member since 2007. Medical Director and founder of Calmark Sweden AB. The inventor of the Calmark method. Responsible for the medical development of the method. Mathias is a M.D. and holds a Ph.D. at Karolinska Institutet, Sweden, within the field of perinatal asphyxia and the unique properties of specific cell damage markers that indicate the physiological status of conditions caused by an insufficient oxygen supply in tissue.
Mats Herdenfeldt, board member since 2009. Mats is a Senior Advisor in corporate finance, turn arounds and business process re-engineering. He has held CEO positions at Data General Nordic Area, NETnet Europe (Telecoms), Danzas 3PL Europe North among others. He has also worked as Corp Product Marketing Director at Data General Inc. in the US. Mats has an extensive experience through seats in over twenty boards.
Måns Olsson, board member since 2010. Måns is Senior Vice President of business development at Diaverum, a renal care provider with operations in Europe, Latin America and Australia. At Diaverum he is in charge of strategy, M&A and new product lines. Previously, Måns was part of Philips’ global corporate strategy team and worked with sales and marketing for Mölnlycke Health Care in Singapore. He started his career as a management consultant with McKinsey & Co. in Gothenburg, Sweden and Singapore. Måns holds a M.Sc. from the Gothenburg School of Economics.
Peter Sjöstrand, board member since 2010. Peter is former CFO and Executive Vice President of Astra AB. Peter is a board member of Active Biotech AB, Oscar Hirsch Memory Foundation, Karolinska Development AB and School of Technology and Health (Royal Institute of Technology), Former Chairman of, inter alia, Meda AB and Gambro AB, and former board member of, inter alia, Swedish leading chain of clinics Aleris AB. Peter holds a B.Sc. from the Stockholm School of Economics and an MD from the Karolinska Institutet, Sweden
Marcus Lüttgen, board member since 2012. Mr. Lüttgen is Senior Analyst and Co-Manager at Alecta, one of the largest pension funds in Europe. He has been working at Alecta for 10 years and gained broad experience within equity research, portfolio management and corporate governance. He has an extensive network within the healthcare industry. Mr. Lüttgen started his career in management consulting and investment banking. He holds a M. Sc. in Finance from the Stockholm School of Economics, a CEMS Master from the University St Gallen and a M. Sc. in Computer and Systems Sciences from the Royal Institute of Technology/Stockholm University.